Univariable and multivariable logistic regression analyses were used to evaluate the association between mounting a strong antibody response and key covariables of interest. Qi, Karen Colwill, Anne-Claude Gingras, Michelle A. Hladunewich and Adeera Levin in Canadian Journal of Kidney Health and Disease sj-jpeg-2-cjk-10.1177_20543581231224127 C Supplemental material for Humoral Response Following 3 Doses of mRNA COVID-19 Vaccines in Patients With Non-Dialysis-Dependent CKD: An Observational Study sj-jpeg-2-cjk-10.1177_20543581231224127.jpeg (939K) GUID:?C8CEBE33-DAE4-40B7-BF77-FFA907EC18DF Supplemental material, sj-jpeg-2-cjk-10.1177_20543581231224127 for Humoral Response Following 3 Doses of mRNA COVID-19 Vaccines in Patients With Non-Dialysis-Dependent CKD: An Observational Study by Omosomi Enilama, Kevin Yau, Lee Er, Mohammad Atiquzzaman, Matthew J. Oliver, Marc G. Romney, Jerome A. Leis, Kento T. Abe, Freda Qi, Karen Colwill, Anne-Claude Gingras, Michelle A. Hladunewich and Adeera Levin in Canadian Journal of Kidney Health and Disease Abstract Background: Chronic kidney disease (CKD) is usually associated with a lower serologic Mirodenafil response to vaccination compared to Rabbit Polyclonal to PPIF the general populace. There is limited information regarding the serologic response to coronavirus disease 2019 (COVID-19) vaccination in the non-dialysis-dependent CKD (NDD-CKD) populace, particularly after the third dose and whether this response varies by estimated glomerular filtration rate (eGFR). Methods: The NDD-CKD (G1-G5) patients who received 3 doses of mRNA COVID-19 vaccines were recruited from renal clinics within British Columbia and Ontario, Canada. Between August 27, 2021, and November 30, 2022, blood samples were collected serially for serological testing every 3 months within a 9-month follow-up period. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike, anti-receptor binding domain (RBD), and anti-nucleocapsid protein (NP) levels were determined by enzyme-linked immunosorbent assay (ELISA). Results: Among 285 NDD-CKD patients, the median age was 67 (interquartile range [IQR], 52-77) years, 58% were men, 48% received BNT162b2 as their third dose, 22% were on immunosuppressive treatment, and COVID-19 contamination by anti-NP seropositivity was observed in 37 of 285 (13%) patients. Following the third dose, anti-spike and anti-RBD levels peaked at 2 months, with geometric mean levels at 1131 and 1672 binding antibody models per milliliter (BAU/mL), respectively, and seropositivity rates above 93% and 85%, respectively, over the 9-month follow-up period. There was no association between eGFR or urine albumin-creatinine ratio (ACR) with mounting a strong antibody response or in antibody Mirodenafil levels over time. The NDD-CKD patients on immunosuppressive treatment were less likely Mirodenafil to mount a strong anti-spike response in univariable (odds Mirodenafil ratio [OR] 0.43, 95% confidence interval [CI]: 0.20, 0.93) and multivariable (OR 0.52, 95% CI: 0.25, 1.10) analyses. An conversation between age, immunoglobulin G (IgG) antibody levels, and time was observed in both unadjusted (anti-spike: = .005; anti-RBD: = .03) and adjusted (anti-spike: = .004; anti-RBD: = .03) models, with older individuals having a more pronounced decline in antibody levels over time. Conclusion: Most NDD-CKD patients were seropositive for anti-spike and anti-RBD after 3 doses of mRNA COVID-19 vaccines and we did not observe any differences in the antibody response by eGFR. Keywords: COVID-19, serology, vaccine, chronic kidney disease, non-dialysis-dependent Background The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has been a major cause of morbidity and mortality worldwide since December 2019. 1 Several studies have shown that this older adults and people with kidney disease are at an increased risk of COVID-19-related mortality, hospitalization, and adverse outcomes.2 -4 Chronic kidney disease (CKD) is marked by chronic inflammation and immune dysfunction that usually results in lower rates of seroconversion, lower antibody levels, and a less sustained humoral response to vaccination compared with the general populace.5 -7 In addition, some studies have demonstrated a graded antibody response by estimated glomerular filtration rate (eGFR) in CKD patients after hepatitis B vaccination.8,9 The BNT162b2 Pfizer-BioNTech and mRNA-1273 Moderna COVID-19 Mirodenafil vaccines were found to be highly efficacious against ancestral SARS-CoV-2 in randomized controlled trials but largely excluded patients with CKD or on immunosuppressive treatment.10,11 To date, a limited number of studies have investigated the COVID-19 vaccine response in patients with non-dialysis-dependent CKD (NDD-CKD).12 -15 In addition, most of these studies looked at the response to 2 doses and were conducted prior to the emergence of some of the more novel variants of concerns, including Omicron (B.1.1.529). One study reported anti-spike levels to be slightly reduced but comparable to healthy controls after a 2-dose regimen of the mRNA-1273 vaccine. 13 There is scarce information regarding the response to 3 doses of.